Hyperthyroidism induced by pembrolizumab
10.3760/cma.j.cn114015-20210222-00205
- VernacularTitle:帕博利珠单抗致甲状腺功能亢进
- Author:
Zhiyuan MAO
1
;
Yu WANG
1
;
Juqin LIU
1
;
Yibing YAO
1
;
Haiyan YU
1
;
Ying JIN
1
;
Xiuling XIA
1
;
Lulu SUN
1
;
Zaiwen FAN
1
Author Information
1. 中国人民解放军空军特色医学中心肿瘤科，北京 100142
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents, immunological;
Hyperthyroidism;
Pembrolizumab;
Drugrelated side effects and adverse reactions;
Case report
- From:
Adverse Drug Reactions Journal
2021;23(12):663-665
- CountryChina
- Language:Chinese
-
Abstract:
A 71-year-old male patient with advanced lung adenocarcinoma received pemetrexed (0.8 g, IV infusion on the first day) and carboplatin (500 mg, IV infusion on the first day) combined with pembrolizumab (200 mg, IV infusion on the second day) and 21 days was a cycle. Before the third cycle of treatment, the patient developed palpitations, irritability, increased appetite, and emaciation. Laboratory tests showed triiodothyronine (T 3) 2.88 nmol/L, thyroxine (T 4) 247.90 nmol/L, free triiodothyronine (FT 3) 10.57 pmol/L, free thyroxine (FT 4) 39.63 pmol/L, thyroid stimulating hormone (TSH) 0.014 mU/L, anti-thyroglobulin antibody (TGAb) 15.9 μg/L, thyroid peroxidase antibody (TPOAb) >1 300.0 kU/L. Immunerelated hyperthyroidism was considered, which may be related to pembrolizumab. The above-mentioned treatment was continued due to the patient′s condition, and thiamazole and metoprolol were given orally at the same time. One month later, laboratory tests showed T 3 2.50 nmol/L, T 4 153.40 nmol/L, FT 3 7.70 pmol/L, FT 4 33.61 pmol/L, TSH 0.007 mU/L, TGAb 15.7 μg/L and TPOAb >1 300.0 kU/L; 2 months later, laboratory tests showed T 3 1.84 nmol/L, T 4 81.20 nmol/L, FT 3 3.86 pmol/L, FT 4 11.56 pmol/L, TSH 1.979 mU/L, TGAb 15.7 μg/L, and TPOAb >1 300.0 kU/L. His symptoms of palpitation and irritability were alleviated.
